| 000 | 01704 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250515132916.0 | ||
| 264 | 0 | _c20090105 | |
| 008 | 200901s 0 0 eng d | ||
| 022 | _a1468-1331 | ||
| 024 | 7 |
_a10.1111/j.1468-1331.2008.02242.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSkeie, G O | |
| 245 | 0 | 0 |
_aParaneoplastic myasthenia gravis: immunological and clinical aspects. _h[electronic resource] |
| 260 |
_bEuropean journal of neurology _cOct 2008 |
||
| 300 |
_a1029-33 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Review | ||
| 650 | 0 | 4 | _aAge of Onset |
| 650 | 0 | 4 | _aAtrophy |
| 650 | 0 | 4 |
_aAutoantibodies _ximmunology |
| 650 | 0 | 4 |
_aAutoantigens _ximmunology |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aConnectin |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aHyperplasia |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMuscle Proteins _ximmunology |
| 650 | 0 | 4 |
_aMyasthenia Gravis _xdrug therapy |
| 650 | 0 | 4 |
_aNerve Tissue Proteins _ximmunology |
| 650 | 0 | 4 |
_aParaneoplastic Polyneuropathy _xdrug therapy |
| 650 | 0 | 4 | _aPlasmapheresis |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aProtein Kinases _ximmunology |
| 650 | 0 | 4 |
_aReceptors, Cholinergic _ximmunology |
| 650 | 0 | 4 |
_aRyanodine Receptor Calcium Release Channel _ximmunology |
| 650 | 0 | 4 | _aThymectomy |
| 650 | 0 | 4 |
_aThymoma _xcomplications |
| 650 | 0 | 4 |
_aThymus Gland _xpathology |
| 650 | 0 | 4 |
_aThymus Neoplasms _xcomplications |
| 700 | 1 | _aRomi, F | |
| 773 | 0 |
_tEuropean journal of neurology _gvol. 15 _gno. 10 _gp. 1029-33 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1468-1331.2008.02242.x _zAvailable from publisher's website |
| 999 |
_c18189818 _d18189818 |
||